Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 11, 2025 08:33 ET | Source: Kaerus Bioscience

Kaerus Bioscience Successfully Completes Phase 1 Trial and Demonstrates Proof of Mechanism with its Novel BK Channel Modulator KER-0193 being developed for Fragile X Syndrome

Kaerus announces its novel BK channel modulator KER-0193 is safe and well tolerated in Phase 1, also demonstrating proof of mechanism with EEG biomarker.
March 11, 2025 06:00 ET | Source: Kaerus Bioscience

Kaerus Bioscience Successfully Completes Phase 1 Trial and Demonstrates Proof of Mechanism with its Novel BK Channel Modulator KER-0193 being developed for Fragile X Syndrome

Kaerus announces its novel BK channel modulator KER-0193 is safe and well tolerated in Phase 1, also demonstrating proof of mechanism with EEG biomarker.
July 26, 2024 00:29 ET | Source: Kaerus Bioscience

Kaerus Bioscience anuncia el inicio de la Fase 1 del ensayo clínico para su nuevo modulador del canal BK KER-0193 que se está desarrollando para el síndrome X frágil

LONDRES, July 26, 2024 (GLOBE NEWSWIRE) -- Kaerus Bioscience Ltd. (www.kaerusbio.com), una empresa de biotecnología en fase clínica centrada en el desarrollo de tratamientos para síndromes genéticos...
July 26, 2024 00:29 ET | Source: Kaerus Bioscience

Kaerus Bioscience annuncia l'avvio di uno studio clinico di fase 1 per lo sviluppo del suo nuovo modulatore dei canali BK KER-0193 per la sindrome dell'X fragile

LONDRA, July 26, 2024 (GLOBE NEWSWIRE) -- Kaerus Bioscience Ltd. (www.kaerusbio.com), azienda biotecnologica in fase clinica specializzata nello sviluppo di terapie per sindromi genetiche rare del...
July 26, 2024 00:29 ET | Source: Kaerus Bioscience

Kaerus Bioscience kündigt Beginn einer klinischen Phase-I-Studie für die Entwicklung des neuartigen BK-Kanal-Modulators KER-0193 gegen das Fragile-X-Syndrom an

LONDON, July 26, 2024 (GLOBE NEWSWIRE) -- Kaerus Bioscience Ltd. (www.kaerusbio.com), ein in der klinischen Phase tätiges Biotechnologieunternehmen, das sich auf die Entwicklung von Therapeutika für...
July 26, 2024 00:29 ET | Source: Kaerus Bioscience

Kaerus Bioscience annonce le lancement de l’essai clinique de phase I ciblé sur son nouveau modulateur de canal BK KER-0193 en cours de développement pour le syndrome de l’X fragile

LONDRES, 26 juill. 2024 (GLOBE NEWSWIRE) -- Kaerus Bioscience Ltd. (www.kaerusbio.com), une société de biotechnologie au stade clinique axée sur le développement de traitements pour les syndromes...
July 26, 2024 00:29 ET | Source: Kaerus Bioscience

Kaerus Bioscience kondigt de start aan van Fase 1 klinische studie voor zijn nieuwe BK-kanaalmodulator KER-0193, die wordt ontwikkeld voor het fragiele-X-syndroom

LONDEN, July 26, 2024 (GLOBE NEWSWIRE) -- Kaerus Bioscience Ltd. (www.kaerusbio.com), een biotechnologiebedrijf dat zich richt op de ontwikkeling van therapeutica voor zeldzame genetische syndromen...
July 25, 2024 05:00 ET | Source: Kaerus Bioscience

Kaerus Bioscience Announces Initiation of Phase 1 Clinical Trial for its Novel BK Channel Modulator KER-0193 being developed for Fragile X Syndrome

LONDON, July 25, 2024 (GLOBE NEWSWIRE) -- Kaerus Bioscience Ltd. (www.kaerusbio.com), a clinical-stage biotechnology company focused on developing therapeutics for rare genetic syndromes of...